Sartorius Stedim Biotech
€208.20Change from previous close: +0.97%Absolute change: +€2.00
At a glance
- Revenue growth
- +6.74%
- 2025 vs 2024
- Net income growth
- +51.68%
- 2025 vs 2024
- Net margin
- 9.0%
- 2024: 6.3%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | 692 | 815 | 746 | 612 | — |
| Depreciation and amortization | 318 | 302 | 237 | 182 | — |
| Capital expenditure | -393 | -340 | -474 | -431 | — |
| Investing cash flow | -398 | -340 | -2,723 | -958 | — |
| Financing cash flow | -543 | 84.9 | 1,986 | 221 | — |
| Dividends paid | -67.1 | -67.1 | -133 | -116 | — |
| Share repurchases | — | -1.9 | — | — | — |
| Debt issued | 13.3 | 17.3 | 2,649 | 567 | — |
| Debt repaid | -335 | -879 | -326 | -174 | — |
| Effect of exchange rates | -4.5 | 2.3 | -0.3 | 8.0 | — |
| Net change in cash | -248 | 560 | 9.8 | -125 | — |
| Free cash flow | 299 | 475 | 273 | 182 | — |